Anaheim, Calif. -- Though Gleevec has shown "wonder drug" capabilities for treating chronic myelogenous leukemia and other cancers, experience in treating patients has revealed some shortcomings. In ...

Each mutation hampers Gleevec's ability to bind to its target, the ABL kinase. In the case of both Gleevec and BMS-354825, there appears to be one particular mutation, known as T315I, which does not ...

Researchers at the Jackson Laboratory, in collaboration with scientists at Bristol-Myers Squibb Oncology, discovered is that imatinib does not inactivate all BCR-ABL signaling pathways in the cascade.

Cepheid and Novartis also will develop a next generation test, which is expected to enable even more sensitive testing, indicating the depth of a patient's response to tyrosine kinase inhibitors, ...

Novartis boasts an accelerated approval for its Gleevec follow-on drug Scemblix in previously treated chronic myeloid leukemia. Now with new clinical data, the company hopes to turn it into a full nod ...

Clinical Research Division investigators and colleagues have reported the first use of a sensitive molecular test to measure precisely the extent of remission in cancer patients undergoing drug ...

Gleevec is a beacon of sorts, a herald of the new era of molecular medicine. It was one of the first cancer drugs to target a specific molecular cause of cancer, rather than more general features such ...

A team of researchers has concluded that the cancer drug Gleevec may cause serious heart damage. They found evidence that imatinib was linked to the heart failure experienced by 10 patients. But ...